Table 1 Relationship between IL-17 and... | American Society of Hematology

Table 1

Relationship between IL-17 and clinical pathologic characteristics in ovarian cancer patients

Variable	Unadjusted HR (95% CI)	Adjusted HR† (95% CI)
Age*	1.003 (0.98-1.03)	NA
Stage, II/III vs IV	1.84 (0.97-3.48)	NA
Grade, 0-2 vs 3	1.74 (0.80-3.78)	NA
Histology type, serous/mucinous/endometrial versus clear cells and undifferentiated	1.36 (0.69-2.69)	NA
Debulking, optimal versus suboptimal residual disease	0.17 (0.07-0.42)	0.189 (0.078-0.458)
IL-17*	0.994 (0.992-0.997)	0.994 (0.991-0.997)

Variable	Unadjusted HR (95% CI)	Adjusted HR† (95% CI)
Age*	1.003 (0.98-1.03)	NA
Stage, II/III vs IV	1.84 (0.97-3.48)	NA
Grade, 0-2 vs 3	1.74 (0.80-3.78)	NA
Histology type, serous/mucinous/endometrial versus clear cells and undifferentiated	1.36 (0.69-2.69)	NA
Debulking, optimal versus suboptimal residual disease	0.17 (0.07-0.42)	0.189 (0.078-0.458)
IL-17*	0.994 (0.992-0.997)	0.994 (0.991-0.997)

NA indicates not applicable.

Age (in years) and IL-17 (in pg/mL) are continuous variables. Other variables are binary, as noted.

†

Adjusted HRs are based on a multivariable Cox proportional hazards model with debulking (binary: optimal vs suboptimal) and IL-17 (continuous) as covariates.

View Large

This Feature Is Available To Subscribers Only